First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

M Liau, Linda; Ashkan, Keyoumars; D Tran, David; L Campian, Jian; E Trusheim, John; S Cobbs, Charles; A Heth, Jason; Salacz, Michael; Taylor, Sarah; D D'Andre, Stacy; M Iwamoto, Fabio; J Dropcho, Edward; A Moshel, Yaron; A Walter, Kevin; P Pillainayagam, Clement; Aiken, Robert; Chaudhary, Rekha; A Goldlust, Samuel; A Bota, Daniela; Duic, Paul; Grewal, Jai; Elinzano, Heinrich; A Toms, Steven; O Lillehei, Kevin; Mikkelsen, Tom; Walbert, Tobias; R Abram, Steven; J Brenner, Andrew; Brem, Steven; G Ewend, Matthew; Khagi, Simon; Portnow, Jana; J Kim, Lyndon; G Loudon, William; C Thompson, Reid; E Avigan, David; L Fink, Karen; J Geoffroy, Francois; Lindhorst, Scott; Lutzky, Jose; E Sloan, Andrew; Schackert, Gabriele; Krex, Dietmar; Meisel, Hans-Jorg; Wu, Julian; P Davis, Raphael; Duma, Christopher; B Etame, Arnold; Mathieu, David; Kesari, Santosh

doi:10.1186/s12967-018-1507-6

Public

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Shared by NobleBlocks on May 29, 2018 • 12:00 AM UTC

Authors:

Linda M Liau

Keyoumars Ashkan

David D Tran

Abstract

BACKGROUND: Standard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) to standard therapy for newly diagnosed glioblastoma. METHODS: After surgery and chemoradio...

Subject

Dendritic cell

Glioblastoma

Immunotherapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!